Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,totalCurrentAssets,longTermDebt,accountsPayable,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,totalCashFromOperatingActivities,changeToNetincome,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,shortName,esgPopulated,tradeable,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchangeDataDelayedBy,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,longName,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jan 14, 2010) 4","Short Ratio (Jan 14, 2010) 4","Short % of Float (Jan 14, 2010) 4","Short % of Shares Outstanding (Jan 14, 2010) 4","Shares Short (prior month Dec 14, 2009) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,INTI,-7359410,375876000,3880,,-127838,,-127838,163873,0,-167753,-167753,,-1685,,,,0,0,167753,0,39915,,-127838,-177153,49952631,3536610,-7359410,58625,138066,37588,-57349629,3000000,17085,84189,432610,52000,120981,104000,321985,36755,101000,101000,2823,9130,-91870,-3610,-311629,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,INHIBITOR THERAPEUTICS INC,False,False,PNK,0.133,1630333756,0.0,0.133,0.133,0.133,5349,PRE,0,4,0.0,0.133 - 0.133,0.133,finmb_369680,"Inhibitor Therapeutics, Inc.",Other OTC,USD,17450,9400,0.111,5.0454545,0.022 - 0.349,-0.216,-0.6189112,0.022,0.349,-0.01,-0.016,0.21514286,-0.08214286,-0.3818061,0.13763043,-0.0046304315,-0.03364395,49991508,-8.3125,15,America/New_York,EDT,-14400000,-0.52,,,0.349,0.022,0.2151,0.1376,17.45k,9.4k,375.88M,,77.9M,78.43%,0.00%,19.88k,0.07,0.36%,0.23%,40,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-196.43%,,,,,,,-1M,-0.0100,,84.19k,0,156k,,0.28,-0.02,-416.1k,-230.68k,Value,33602,Healthcare,1,"Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.",Tampa,888 841 6811,FL,1609372800,United States,http://www.inhibitortx.com,86400,449 South 12th Street,813 830 7489,Biotechnology,Unit 1705
t-1,INTI,-7321069,375876000,2710,,-55851,,-55851,53027,0,-55737,-55737,,-114,,,,0,0,55737,0,-114,,-55851,-106262,49814043,3491962,-7321069,125946,131759,37364,-57172476,3000000,24408,75059,425406,30044,107351,66556,269416,-90456,55000,55000,10323,38352,-16648,119336,-318055,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,INHIBITOR THERAPEUTICS INC,False,False,PNK,0.133,1630333756,0.0,0.133,0.133,0.133,5349,PRE,0,4,0.0,0.133 - 0.133,0.133,finmb_369680,"Inhibitor Therapeutics, Inc.",Other OTC,USD,17450,9400,0.111,5.0454545,0.022 - 0.349,-0.216,-0.6189112,0.022,0.349,-0.01,-0.016,0.21514286,-0.08214286,-0.3818061,0.13763043,-0.0046304315,-0.03364395,49991508,-8.3125,15,America/New_York,EDT,-14400000,-0.52,,,0.349,0.022,0.2151,0.1376,17.45k,9.4k,375.88M,,77.9M,78.43%,0.00%,19.88k,0.07,0.36%,0.23%,40,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-196.43%,,,,,,,-1M,-0.0100,,84.19k,0,156k,,0.28,-0.02,-416.1k,-230.68k,Value,33602,Healthcare,1,"Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.",Tampa,888 841 6811,FL,1609372800,United States,http://www.inhibitortx.com,86400,449 South 12th Street,813 830 7489,Biotechnology,Unit 1705
t-2,INTI,-7334143,375876000,32468,,-302767,,-302767,270306,0,-302774,-302774,,-114,,,,0,0,302774,0,7,,-302767,-353178,49694707,3477007,-7334143,183876,103730,37364,-57066214,3000000,31731,36707,458518,23111,71999,18489,251531,140144,55000,55000,12060,-100610,-100610,49953,-386519,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,INHIBITOR THERAPEUTICS INC,False,False,PNK,0.133,1630333756,0.0,0.133,0.133,0.133,5349,PRE,0,4,0.0,0.133 - 0.133,0.133,finmb_369680,"Inhibitor Therapeutics, Inc.",Other OTC,USD,17450,9400,0.111,5.0454545,0.022 - 0.349,-0.216,-0.6189112,0.022,0.349,-0.01,-0.016,0.21514286,-0.08214286,-0.3818061,0.13763043,-0.0046304315,-0.03364395,49991508,-8.3125,15,America/New_York,EDT,-14400000,-0.52,,,0.349,0.022,0.2151,0.1376,17.45k,9.4k,375.88M,,77.9M,78.43%,0.00%,19.88k,0.07,0.36%,0.23%,40,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-196.43%,,,,,,,-1M,-0.0100,,84.19k,0,156k,,0.28,-0.02,-416.1k,-230.68k,Value,33602,Healthcare,1,"Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.",Tampa,888 841 6811,FL,1609372800,United States,http://www.inhibitortx.com,86400,449 South 12th Street,813 830 7489,Biotechnology,Unit 1705
t-3,INTI,-7231466,375876000,52661,,-314894,,-314894,262383,0,-315044,-315044,,-114,,,,0,0,315044,0,150,,-314894,-364757,49444525,3487000,-7231466,286892,216400,37045,-56713036,3000000,39054,137317,461578,16178,177346,25422,158508,49637,41600,41600,15533,-165371,-206971,42753,-284232,en-US,US,EQUITY,False,Delayed Quote,USD,us_market,INHIBITOR THERAPEUTICS INC,False,False,PNK,0.133,1630333756,0.0,0.133,0.133,0.133,5349,PRE,0,4,0.0,0.133 - 0.133,0.133,finmb_369680,"Inhibitor Therapeutics, Inc.",Other OTC,USD,17450,9400,0.111,5.0454545,0.022 - 0.349,-0.216,-0.6189112,0.022,0.349,-0.01,-0.016,0.21514286,-0.08214286,-0.3818061,0.13763043,-0.0046304315,-0.03364395,49991508,-8.3125,15,America/New_York,EDT,-14400000,-0.52,,,0.349,0.022,0.2151,0.1376,17.45k,9.4k,375.88M,,77.9M,78.43%,0.00%,19.88k,0.07,0.36%,0.23%,40,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-196.43%,,,,,,,-1M,-0.0100,,84.19k,0,156k,,0.28,-0.02,-416.1k,-230.68k,Value,33602,Healthcare,1,"Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.",Tampa,888 841 6811,FL,1609372800,United States,http://www.inhibitortx.com,86400,449 South 12th Street,813 830 7489,Biotechnology,Unit 1705
